Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Celcuity presents data at AACR annual meeting assessing gedatolisib » 16:12
04/12/21
04/12
16:12
04/12/21
16:12
CELC

Celcuity

$27.39 /

+5.98 (+27.93%)

Celcuity presented…

Celcuity presented results of studies evaluating gedatolisib, a pan-PI3K/mTOR inhibitor, inavolisib, a PI3K-alpha inhibitor), and navitoclax, a BCL inhibitor, in breast and ovarian patient tumors. Results were presented in two e-posters at the American Association for Cancer Research, AACR, Annual Meeting. The CELsignia RAS Network Activity test for breast and ovarian cancer identifies patients whose tumors have hyperactive RAS network signaling. The posters presented at AACR describe studies using this CELsignia test to characterize the role RAS network nodes, PI3K, mTOR, and

ShowHide Related Items >><<
CELC Celcuity
$27.39 /

+5.98 (+27.93%)

CELC Celcuity
$27.39 /

+5.98 (+27.93%)

04/12/21 H.C. Wainwright
Celcuity price target raised to $30 from $19 at H.C. Wainwright
02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
  • 24
    Feb
CELC Celcuity
$27.39 /

+5.98 (+27.93%)

Recommendations
Celcuity price target raised to $30 from $19 at H.C. Wainwright » 06:24
04/12/21
04/12
06:24
04/12/21
06:24
CELC

Celcuity

$21.50 /

+7.35 (+51.94%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on Celcuity to $30 from $19 and reiterates a Buy rating on the shares after the company entered into a global licensing agreement with Pfizer (PFE) that grants it exclusive rights to develop and commercialize gedatolisib.

ShowHide Related Items >><<
CELC Celcuity
$21.50 /

+7.35 (+51.94%)

CELC Celcuity
$21.50 /

+7.35 (+51.94%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
  • 24
    Feb
CELC Celcuity
$21.50 /

+7.35 (+51.94%)

Over a week ago
On The Fly
Fly Intel: Pre-market Movers » 08:51
04/09/21
04/09
08:51
04/09/21
08:51
GLSI

Greenwich LifeSciences

$49.29 /

-2.29 (-4.44%)

, AFMD

Affimed N.V.

$7.87 /

+0.08 (+1.03%)

, CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

, FUBO

FuboTV

$20.69 /

-0.06 (-0.29%)

, SUNW

Sunworks

$13.91 /

-0.44 (-3.07%)

, JKS

JinkoSolar

$38.86 /

-0.895 (-2.25%)

, TSM

TSMC

$123.46 /

+3.52 (+2.93%)

, IMOS

ChipMOS

$33.62 /

+1.62 (+5.06%)

, GSL

Global Ship Lease

$14.01 /

-0.51 (-3.51%)

, PRVB

Provention Bio

$9.73 /

-0.25 (-2.51%)

Check out this morning's…

ShowHide Related Items >><<
TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

AFMD Affimed N.V.
$7.87 /

+0.08 (+1.03%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

AFMD Affimed N.V.
$7.87 /

+0.08 (+1.03%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
03/09/21 Oppenheimer
FuboTV price target lowered to $35 from $45 at Oppenheimer
03/08/21 Alliance Global Partners
Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners
SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
TSM TSMC
$123.46 /

+3.52 (+2.93%)

04/01/21 DA Davidson
Onto Innovation price target raised to $80 from $75 at DA Davidson
03/29/21 Citi
TSMC recent selloff brings 'enhanced buying opportunity,' says Citi
03/25/21 Northland
Northland upgrades AMD to Outperform on Intel's 'strategic faux pas'
03/24/21 Jefferies
Intel price target raised to $59 from $57 at Jefferies
IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

02/12/21
Fly Intel: Top five analyst initiations
02/12/21 Jefferies
Global Ship Lease initiated with a Buy at Jefferies
01/15/21 B. Riley
Global Ship Lease price target raised to $20 from $16 at B. Riley Securities
01/06/21 B. Riley
Global Ship Lease price target raised to $16 from $12 at B. Riley Securities
PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
02/25/21 Chardan
Provention Bio price target lowered to $35 from $40 at Chardan
TSM TSMC
$123.46 /

+3.52 (+2.93%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

  • 09
    Apr
  • 24
    Feb
  • 22
    Jan
  • 14
    Jan
  • 13
    Jan
  • 30
    Dec
  • 18
    Dec
  • 08
    Oct
  • 25
    Sep
  • 18
    Jun
TSM TSMC
$123.46 /

+3.52 (+2.93%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

AFMD Affimed N.V.
$7.87 /

+0.08 (+1.03%)

TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

On The Fly
Fly Intel: After-Hours Movers » 18:36
04/08/21
04/08
18:36
04/08/21
18:36
LEVI

Levi Strauss

$25.04 /

+0.52 (+2.12%)

, CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

, GTIM

Good Times Restaurants

$4.55 /

-0.35 (-7.14%)

, FUBO

FuboTV

$20.69 /

-0.06 (-0.29%)

, CCK

Crown Holdings

$101.99 /

+1.02 (+1.01%)

, WDFC

WD-40

$310.22 /

+2.65 (+0.86%)

, LEDS

SemiLEDs

$5.37 /

+0.47 (+9.59%)

, PSMT

PriceSmart

$96.34 /

+0.33 (+0.34%)

, PRVB

Provention Bio

$9.73 /

-0.25 (-2.51%)

Check out this evening's…

ShowHide Related Items >><<
WDFC WD-40
$310.22 /

+2.65 (+0.86%)

PSMT PriceSmart
$96.34 /

+0.33 (+0.34%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

LEVI Levi Strauss
$25.04 /

+0.52 (+2.12%)

GTIM Good Times Restaurants
$4.55 /

-0.35 (-7.14%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

CCK Crown Holdings
$101.99 /

+1.02 (+1.01%)

LEVI Levi Strauss
$25.04 /

+0.52 (+2.12%)

01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
12/30/20 Guggenheim
Levi Strauss price target raised to $24 from $20 at Guggenheim
12/10/20
Fly Intel: Top five analyst upgrades
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
GTIM Good Times Restaurants
$4.55 /

-0.35 (-7.14%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
03/09/21 Oppenheimer
FuboTV price target lowered to $35 from $45 at Oppenheimer
03/08/21 Alliance Global Partners
Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners
CCK Crown Holdings
$101.99 /

+1.02 (+1.01%)

02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
01/20/21 Deutsche Bank
Crown Holdings price target raised to $112 from $104 at Deutsche Bank
WDFC WD-40
$310.22 /

+2.65 (+0.86%)

02/19/21
Fly Intel: Top five analyst downgrades
02/19/21 DA Davidson
WD-40 cut to Neutral from Buy at DA Davidson on hard comps, rising input costs
02/19/21 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
01/08/21 DA Davidson
WD-40 price target raised to $353 from $250 at DA Davidson
LEDS SemiLEDs
$5.37 /

+0.47 (+9.59%)

PSMT PriceSmart
$96.34 /

+0.33 (+0.34%)

05/08/20 Scotiabank
Scotiabank downgrades PriceSmart amid COVID-19 restrictions
05/08/20 Scotiabank
PriceSmart downgraded to Sector Perform from Outperform at Scotiabank
PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

02/25/21 Chardan
Provention Bio price target lowered to $35 from $40 at Chardan
02/22/21 H.C. Wainwright
Provention Bio price target raised to $34 from $26 at H.C. Wainwright
01/04/21 Chardan
Provention Bio price target raised to $40 from $35 at Chardan
11/02/20 Chardan
Provention Bio remains top pick for 2020 at Chardan
WDFC WD-40
$310.22 /

+2.65 (+0.86%)

PSMT PriceSmart
$96.34 /

+0.33 (+0.34%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

LEVI Levi Strauss
$25.04 /

+0.52 (+2.12%)

LEDS SemiLEDs
$5.37 /

+0.47 (+9.59%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CCK Crown Holdings
$101.99 /

+1.02 (+1.01%)

  • 24
    Feb
  • 14
    Jan
  • 30
    Dec
  • 08
    Oct
  • 18
    Jun
CCK Crown Holdings
$101.99 /

+1.02 (+1.01%)

WDFC WD-40
$310.22 /

+2.65 (+0.86%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

LEVI Levi Strauss
$25.04 /

+0.52 (+2.12%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CCK Crown Holdings
$101.99 /

+1.02 (+1.01%)

WDFC WD-40
$310.22 /

+2.65 (+0.86%)

PSMT PriceSmart
$96.34 /

+0.33 (+0.34%)

LEVI Levi Strauss
$25.04 /

+0.52 (+2.12%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

Hot Stocks
Celcuity Inc trading resumes  16:35
04/08/21
04/08
16:35
04/08/21
16:35
CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

 
ShowHide Related Items >><<
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
  • 24
    Feb
Hot Stocks
Celcuity reports preliminary data from Phase 1b gedatolisib plus Ibrance trial » 16:06
04/08/21
04/08
16:06
04/08/21
16:06
CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

Celcuity reported…

Celcuity reported preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus Ibrance and endocrine therapy, in ER+/HER2- advanced or metastatic breast cancer patients. As of the January 11, 2021 data cut-off date, 53 of the 88 evaluable patients had an objective response. Gedatolisib was also generally well tolerated, with the majority of treatment-related adverse events being Grade 1 or 2. The most common Grade 3 or 4 TRAEs related to gedatolisib were stomatitis and rash. "We are very encouraged by this preliminary data for gedatolisib from our ongoing Phase 1b trial in patients with breast cancer," said Brian Sullivan, CEO and Co-Founder of Celcuity. "The robust response rate and the observed tolerability profile are particularly compelling given the need for a therapeutic regimen that can address endocrine therapy resistance. We look forward to sharing additional data from the study at a future medical conference in 2021. Developing a therapeutic such as gedatolisib allows us to more fully leverage our CELsignia cellular analysis platform."

ShowHide Related Items >><<
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
  • 24
    Feb
Hot Stocks
Celcuity announces gedatolisib licensing agreement with Pfizer » 16:03
04/08/21
04/08
16:03
04/08/21
16:03
CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

, PFE

Pfizer

$35.92 /

+0.01 (+0.03%)

Celcuity (CELC) announced…

Celcuity (CELC) announced it has entered into a global licensing agreement with Pfizer Inc. (PFE) granting Celcuity exclusive rights to Pfizer's gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor. Gedatolisib is in clinical development for the treatment of patients with ER+/HER2-negative advanced or metastatic breast cancer. Under the terms of the licensing agreement, Pfizer provided Celcuity with a worldwide license to develop and commercialize gedatolisib. Celcuity paid an upfront license fee of $5M of cash and $5M of Celcuity's common stock as upfront payment. Pfizer is eligible to receive up to $330M of development and sales-based milestone payments and tiered royalties on potential sales. Additional financial terms of the agreement were not disclosed. "We are excited about the opportunity to utilize our CELsignia platform to support the development of a potential first-in-class targeted therapy like gedatolisib," said Brian Sullivan, CEO and co-founder of Celcuity. "In light of the important role the PI3K/mTOR pathway plays in driving tumor growth when patients become resistant to endocrine therapies, we believe gedatolisib is a highly promising drug candidate to improve outcomes for patients with breast cancer. Supporting development of a potential first-in-class therapy for breast cancer, such as gedatolisib, with our CELsignia platform is a natural extension of our strategy to develop CELsignia CDx for other breast cancer therapies. We believe developing targeted therapies that benefit from the CELsignia platform while also offering companion diagnostics that enable new drug indications, creates a synergistic advantage for each program."

ShowHide Related Items >><<
PFE Pfizer
$35.92 /

+0.01 (+0.03%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
PFE Pfizer
$35.92 /

+0.01 (+0.03%)

04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
PFE Pfizer
$35.92 /

+0.01 (+0.03%)

  • 24
    Feb
PFE Pfizer
$35.92 /

+0.01 (+0.03%)

PFE Pfizer
$35.92 /

+0.01 (+0.03%)

PFE Pfizer
$35.92 /

+0.01 (+0.03%)

Hot Stocks
Celcuity Inc trading halted, news pending  16:00
04/08/21
04/08
16:00
04/08/21
16:00
CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

 
ShowHide Related Items >><<
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
  • 24
    Feb
Syndicate
Celcuity files $100M mixed securities shelf  16:47
03/23/21
03/23
16:47
03/23/21
16:47
CELC

Celcuity

$14.65 /

-0.35 (-2.33%)

 
ShowHide Related Items >><<
CELC Celcuity
$14.65 /

-0.35 (-2.33%)

CELC Celcuity
$14.65 /

-0.35 (-2.33%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
  • 24
    Feb
Over a month ago
Syndicate
Celcuity 1.714M share Spot Secondary priced at $14.00 » 08:45
02/24/21
02/24
08:45
02/24/21
08:45
CELC

Celcuity

$15.94 /

-2.05 (-11.40%)

The deal size was…

The deal size was increased to $24M in common stock from $20M in common stock. Craig-Hallum acted as sole book running manager for the offering.

ShowHide Related Items >><<
CELC Celcuity
$15.94 /

-2.05 (-11.40%)

CELC Celcuity
$15.94 /

-2.05 (-11.40%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.